Fig. 4: In vivo multimodal imaging using activated theranostic agent.

a The representative NIR-II FL imaging of the normal muscle tissue (ROI A) and tumor (ROI B) in the thighs of the mice at different times points (0, 0.5, 6, 12, 48 and 60 h) after intratumoral injection of 20 μM DPM-HD3-CO (100 μL, including 10 μM PdCl₂). Imaging parameters: 808 nm laser, 880 nm long-pass filters. b Corresponding mean intensity of NIR-II FL imaging. (n = 5 mice). c PA imaging of tumor regions at different times points (0, 0.5, 6, 12, 48 and 60 h) after intratumoral injection of 20 μM DPM-HD3-CO (100 μL, including 10 μM PdCl₂). The meaning of the colors were indicated in the color bars: The red and green represent PA₉₀₀ channel. The orange and purple represent PA₆₉₀ channel. d Corresponding mean intensity of the PA imaging. (n = 5 mice). e PTI of the tumor exposed to continuous laser irradiation (808 nm, 1 W cm⁻², 0–7 min) after post-injection of PBS and 20 μM DPM-HD3-CO (100 μL, including 10 μM PdCl₂). (n = 5 mice). The yellow represent PTI channels. Imaging effects of NIR-II FLI, PAI, and PTI before and after photothermal treatment (Laser: 808 nm, 1 W cm⁻²). f The corresponding temperature intensity in (e). The excitation source is an 808 nm laser and FLI was collected by 880 nm long-pass filter with an exposure time of 100 ms. Data are presented as the means ± s.d. (n = 5 mice). Source data are provided as a Source Data file.